Abstract

BackgroundMultiple sclerosis (MS) is a neuroinflammatory autoimmune disease of the central nervous system (CNS) which in most cases initially presents with episodes of transient functional deficits (relapsing-remitting MS; RRMS) and eventually develops into a secondary progressive form (SPMS). Aside from neuroimmunological activities, MS is also characterized by neurodegenerative and regenerative processes. The latter involve the restoration of myelin sheaths—electrically insulating structures which are the primary targets of autoimmune attacks. Spontaneous endogenous remyelination takes place even in the adult CNS and is primarily mediated by activation, recruitment, and differentiation of resident oligodendroglial precursor cells (OPCs). However, the overall efficiency of remyelination is limited and further declines with disease duration and progression. From a therapeutic standpoint, it is therefore key to understand how oligodendroglial maturation can be modulated pharmacologically. Teriflunomide has been approved as a first-line treatment for RRMS in the USA and the European Union. As the active metabolite of leflunomide, an established disease-modifying anti-rheumatic drug, it mainly acts via an inhibition of de novo pyrimidine synthesis exerting a cytostatic effect on proliferating B and T cells.MethodsWe investigated teriflunomide-dependent effects on primary rat oligodendroglial homeostasis, proliferation, and differentiation related to cellular processes important for myelin repair hence CNS regeneration in vitro. To this end, several cellular parameters, including specific oligodendroglial maturation markers, in vitro myelination, and p53 family member signaling, were examined by means of gene/protein expression analyses. The rate of myelination was determined using neuron-oligodendrocyte co-cultures.ResultsLow teriflunomide concentrations resulted in cell cycle exit while higher doses led to decreased cell survival. Short-term teriflunomide pulses can efficiently promote oligodendroglial cell differentiation suggesting that young, immature cells could benefit from such stimulation. In vitro myelination can be boosted by means of an early stimulation window with teriflunomide. p73 signaling is functionally involved in promoting OPC differentiation and myelination.ConclusionOur findings indicate a critical window of opportunity during which regenerative oligodendroglial activities including myelination of CNS axons can be stimulated by teriflunomide.

Highlights

  • Multiple sclerosis (MS) is a neuroinflammatory autoimmune disease of the central nervous system (CNS) which in most cases initially presents with episodes of transient functional deficits and eventually develops into a secondary progressive form (SPMS)

  • Since it was recently demonstrated that teriflunomide exerts direct effects on resident CNS cells such as microglia and astrocytes [18], we hypothesized that teriflunomide could affect oligodendroglial homeostasis, proliferation, and differentiation all of which are cellular processes important for myelin repair

  • We investigated the effect of teriflunomide on purified postnatal primary rat Oligodendroglial precursor cell (OPC) that can mature upon mitogen withdrawal by means of time course stimulation and dose dependency analyses

Read more

Summary

Introduction

Multiple sclerosis (MS) is a neuroinflammatory autoimmune disease of the central nervous system (CNS) which in most cases initially presents with episodes of transient functional deficits (relapsing-remitting MS; RRMS) and eventually develops into a secondary progressive form (SPMS). Aside from neuroimmunological activities, MS is characterized by neurodegenerative and regenerative processes The latter involve the restoration of myelin sheaths—electrically insulating structures which are the primary targets of autoimmune attacks. MS is characterized by an infiltration of immune cells into the central nervous system (CNS) followed by an attack directed against the myelin-producing cells of the CNS, the oligodendrocytes. Their demise results in myelin sheath degeneration, leading to a reduction of axonal conductivity as well as, neurodegeneration [1]. Currently available DMTs only slow down disease progression and decrease the development of new lesions but do not directly promote repair via restoring myelin. The therapeutic goal to promote long-term repair of existing lesions is still unmet

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call